Enhanced delivery of carboplatin into brain tumours with intravenous Cereport™ (RMP-7):: dramatic differences and insight gained from dosing parameters

被引:50
作者
Emerich, DF
Snodgrass, P
Dean, R
Agostino, M
Hasler, B
Pink, M
Xiong, H
Kim, BS
Bartus, RT
机构
[1] Alkermes Inc, Cambridge, MA 02139 USA
[2] Tufts Univ, Med Ctr, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
关键词
glioma; blood-brain barrier; chemotherapy; drug delivery; tumour barrier;
D O I
10.1038/sj.bjc.6690450
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cereport(TM) (RMP-7) is a selective bradykinin B2 receptor agonist which increases the permeability of the 'blood-brain tumour barrier' (BBTB) to increase delivery of chemotherapeutic agents to brain tumours. A series of experiments was performed in an RG2 rodent model of glioma to evaluate and refine intravenous (i.v.) parameters to optimize Cereport's clinical utility. The first experiment demonstrated that while carboplatin levels were increased by twofold when given as a bolus during the Cereport infusion, no increase in carboplatin levels were seen when Cereport and carboplatin were simultaneously co-infused for 15 min. A subsequent experiment established that a major factor responsible for the lack of an effect with the co-infusion paradigm was tachyphylaxis to Cereport during the 15 min infusion, for a progressively diminished response to Cereport occurred over that time frame, as plasma levels of carboplatin were rising. A final experiment adjusted the timing of the Cereport and carboplatin infusions so that higher plasma carboplatin levels were achieved prior to initiating the Cereport infusion, Significant uptake effects were achieved when the carboplatin infusion preceded the Cereport infusion by 10 min (i.e. 5 min overlap in the delivery of the two agents). Collectively, these data provide the first systematic evaluation of dosing parameters involving receptor-mediated changes in BBTB permeability and provide new information regarding the pharmacodynamics and potential clinical use of Cereport.
引用
收藏
页码:964 / 970
页数:7
相关论文
共 33 条
[1]   Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: Evidence for a sensitive, auto-regulated, receptor-mediated system [J].
Bartus, RT ;
Elliott, P ;
Hayward, N ;
Dean, R ;
McEwen, EL ;
Fisher, SK .
IMMUNOPHARMACOLOGY, 1996, 33 (1-3) :270-278
[2]   Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7 [J].
Bartus, RT ;
Elliott, PJ ;
Dean, RL ;
Hayward, NJ ;
Nagle, TL ;
Huff, MR ;
Snodgrass, PA ;
Blunt, DG .
EXPERIMENTAL NEUROLOGY, 1996, 142 (01) :14-28
[3]   Use of Cereport™ (RMP-7) to increase delivery of carboplatin to gliomas:: Insight and parameters for intracarotid infusion via a single-lumen cannula [J].
Bartus, RT .
DRUG DELIVERY, 1999, 6 (01) :15-21
[4]   Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas [J].
Black, KL ;
Cloughesy, T ;
Huang, SC ;
Gobin, YP ;
Zhou, Y ;
Grous, J ;
Nelson, G ;
Farahani, K ;
Hoh, CK ;
Phelps, M .
JOURNAL OF NEUROSURGERY, 1997, 86 (04) :603-609
[5]   BIOCHEMICAL OPENING OF THE BLOOD-BRAIN-BARRIER [J].
BLACK, KL .
ADVANCED DRUG DELIVERY REVIEWS, 1995, 15 (1-3) :37-52
[6]  
BURCH R, 1993, MOL BIOL PHARM BRADY
[7]  
CHOW KL, 1998, C P AM SOC CLIN ONCO
[8]  
DOCTROW SR, 1994, J PHARMACOL EXP THER, V271, P229
[9]   Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7 [J].
Elliott, PJ ;
Hayward, NJ ;
Dean, RL ;
Bartus, RT .
IMMUNOPHARMACOLOGY, 1996, 33 (1-3) :205-208
[10]   Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy [J].
Elliott, PJ ;
Hayward, NJ ;
Huff, MR ;
Nagle, TL ;
Black, KL ;
Bartus, RT .
EXPERIMENTAL NEUROLOGY, 1996, 141 (02) :214-224